Oral semaglutide can be used as a treatment intensification option even in addition to insulin.[] PIONEER 5 was a randomized, double-blind, placebo-controlled, parallel-group, multicentre, multinational trial that included 324 subjects with T2DM and estimated glomerular filtration rate (eGFR) 3059 mL/min/1.73 m 2 , on stable doses of 12 oral antidiabetic drugs (OADs) (metformin, SU) and/or basal insulin for 90 days randomized to oral semaglutide 14 mg and placebo (1:1)
89: 14681475, doi: Leenders M, Verdijk LB, van der Hoeven L, van Kranenburg J, Hartgens F, Wodzig WK, Saris WH, van Loon LJ
Each pen can deliver about a months worth of medication meaning the treatment can cost nearly $2,000 a year
Understanding your individual risk profile and baseline health markers enables more informed conversations with your provider about dosing strategy and monitoring